WILMINGTON, N.C., Oct. 30, 2008 (GLOBE NEWSWIRE) --
Highlights: Third quarter revenues increased 39% to $6.0 million 671 TranS1 procedures performed in the quarter Gross margin was 83.2% for the quarter GAAP loss per share was $0.23 for the quarter Non-GAAP loss per share was $0.20 for the quarter Limited Market Release of the AxiaLIF 2L, Two Level Percutaneous Lumbar Fusion System Completed
TranS1 Inc. (Nasdaq:TSON), a medical device company focused on designing, developing and marketing products that implement its proprietary minimally invasive surgical approach to treat degenerative disc disease affecting the lower lumbar region of the spine, today announced its financial results for the third quarter ended September 30, 2008.
Revenues were $6.0 million in the third quarter of 2008, representing a 39% increase over revenues of $4.3 million in the third quarter of 2007. Gross margin was 83.2% in the third quarter, an increase from 82.6% in the third quarter of 2007.
Operating expenses were $10.4 million in the third quarter of 2008 compared to $5.9 million in the third quarter of 2007. The increase in operating expenses is primarily attributable to an increase in sales and marketing costs as a result of the continued expansion of the direct sales force, increased commissions as a result of increased sales and increased surgeon training costs. Additionally, general and administrative costs increased primarily due to the addition of personnel and increased legal and professional fees.
Net loss was $4.8 million and $2.2 million for the quarters ended September 30, 2008 and 2007, respectively. GAAP net loss per common share was $0.23 in the third quarter of 2008 compared to a net loss per share of $0.87 in the third quarter of 2007.
For the quarter ended September 30, 2008, on a non-GAAP basis, adjusting for non-cash stock compensation expense, net loss was $0.20 per common share based upon 20,474,000 weighted average common shares outstanding. For the quarter ended September 30, 2007, on a non-GAAP basis, adjusting for non-cash stock compensation expense, the issuance of 6.3 million shares of common stock from the company's initial public offering in October 2007 and the conversion of preferred stock into common stock in connection with the public offering, net loss was $0.08 per common share based upon 19,667,000 weighted average common shares outstanding.
Cash, cash-equivalents and investments were $83.2 million as of September 30, 2008.
"I am pleased with the early impact the AxiaLIF two-level product has had on our domestic business," said Rick Randall, President and Chief Executive Officer of TranS1. "I look forward to future growth driven by the transition from the successful limited release to the national launch of the two-level device combined with the continued maturation of our domestic sales force."
Conference Call
TranS1 will host a conference call today at 4:30 pm EDT to discuss its third quarter financial results. To listen to the conference call on your telephone, please dial 877-548-7906 for domestic callers and 719-325-4917 for international callers approximately ten minutes prior to the start time. The call will be concurrently webcast. To access the live audio broadcast or the subsequent archived recording, visit the TranS1 Web site at www.trans1.com under the investor relations section.
Non-GAAP Measures
Management uses certain non-GAAP financial measures such as non-GAAP net loss and net loss per share, which exclude stock based compensation and include the assumed conversion of preferred stock to common stock. This non-GAAP presentation is given in part to enhance the understanding of the company's historical financial performance and comparability between periods. The company believes that the non-GAAP presentation to exclude stock-based compensation and the assumed conversion of preferred stock to common stock is relevant and useful information that will be widely used by investors and analysts. Accordingly, the company is disclosing this information to permit additional analysis of the company's performance. These non-GAAP measures are not in accordance with, or an alternative for, GAAP, and may be different from non-GAAP measures used by other companies. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures in accordance with GAAP. A reconciliation of the GAAP financial measures to the comparable non-GAAP financial measure is included below.
About TranS1 Inc.
TranS1 is a medical device company focused on designing, developing and marketing products that implement its proprietary minimally invasive surgical approach to treat degenerative disc disease affecting the lower lumbar region of the spine. TranS1 currently markets two single-level fusion products, the AxiaLIF(r) and the AxiaLIF 360:o, and a two-level fusion product, the AxiaLIF 2L, in the US and Europe. TranS1 was founded in May 2000 and is headquartered in Wilmington, North Carolina. For more information, visit www.trans1.com.
Forward-Looking Statements
This press release includes forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. These risks and uncertainties include, among other things, risks associated with the adoption of a new technology by spine surgeons, product development efforts, regulatory requirements, maintenance and prosecution of adequate intellectual property protection and other economic and competitive factors. These forward looking statements are based on the company's expectations as of the date of this press release and the company undertakes no obligation to update information provided in this press release. For a discussion of risks and uncertainties associated with TranS1's business, please review the company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2007.
TranS1 Inc.
Statements of Operations
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended Nine Months Ended
Sept. 30, Sept. 30,
------------------ ------------------
2008 2007 2008 2007
-------- -------- -------- --------
Revenue $ 6,021 $ 4,327 $ 17,950 $ 11,514
Cost of revenue 1,011 754 3,186 2,213
-------- -------- -------- --------
Gross profit 5,010 3,573 14,764 9,301
-------- -------- -------- --------
Operating expenses:
Research and development 1,163 1,320 3,940 3,599
Sales and marketing 7,782 3,780 20,680 10,616
General and administrative 1,418 812 4,864 1,895
-------- -------- -------- --------
Total operating expenses 10,363 5,912 29,484 16,110
-------- -------- -------- --------
Operating loss (5,353) (2,339) (14,720) (6,809)
Interest income 589 125 2,218 468
-------- -------- -------- --------
Net loss $ (4,764) $ (2,214) $(12,502) $ (6,341)
======== ======== ======== ========
Net loss per common share -
basic and diluted $ (0.23) $ (0.87) $ (0.62) $ (2.54)
======== ======== ======== ========
Weighted average common
shares outstanding - basic
and diluted 20,474 2,549 20,206 2,495
======== ======== ======== ========
Stock-based compensation is
included in operating
expenses in the following
categories:
Cost of revenue $ 18 $ 14 $ 45 $ 40
Research and development 99 179 394 378
Sales and marketing 445 400 1,319 1,117
General and administrative 181 121 839 239
-------- -------- -------- --------
$ 743 $ 714 $ 2,597 $ 1,774
======== ======== ======== ========
Reconciliation of Second Quarter Results
(in thousands, except per share amounts)
(Unaudited)
2008 2007
--------- ---------
GAAP net loss $ (4,764) $ (2,214)
Stock based compensation 743 714
--------- ---------
Non-GAAP net loss $ (4,021) $ (1,500)
========= =========
Shares used in computing GAAP loss per share 20,474 2,549
Assumed issuance of common shares from
initial public offering -- 6,325
Assumed conversion of preferred stock to
common stock -- 10,793
--------- ---------
Shares used in computing non-GAAP loss
per share 20,474 19,667
========= =========
Non-GAAP loss per share $ (0.20) $ (0.08)
========= =========
Reconciliation of Year-To-Date Results
(in thousands, except per share amounts)
(Unaudited) 2008 2007
--------- ---------
GAAP net loss $ (12,502) $ (6,341)
Stock based compensation 2,597 1,774
--------- ---------
Non-GAAP net loss $ (9,905) $ (4,567)
========= =========
Shares used in computing GAAP loss per share 20,206 2,495
Assumed issuance of common shares from
initial public offering -- 6,325
Assumed conversion of preferred stock to
common stock -- 10,793
--------- ---------
Shares used in computing non-GAAP loss
per share 20,206 19,613
========= =========
Non-GAAP loss per share $ (0.49) $ (0.23)
========= =========
TranS1 Inc.
Balance Sheets
(in thousands)
(Unaudited)
Sept. 30, Dec. 31,
2008 2007
--------- ---------
Assets
Current assets:
Cash and cash equivalents $ 42,930 $ 64,676
Short-term investments 25,949 29,245
Accounts receivable, net 3,752 3,225
Inventory 5,453 4,025
Prepaid expenses and other assets 401 597
--------- ---------
Total current assets 78,485 101,768
Property and equipment, net 1,508 1,088
Long-term investments 14,331 --
--------- ---------
Total assets $ 94,324 $ 102,856
========= =========
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 2,403 $ 1,631
Accrued expenses 2,198 1,786
--------- ---------
Total current liabilities 4,601 3,417
--------- ---------
Stockholders' equity
Common stock 2 2
Additional paid-in capital 133,111 130,325
Accumulated deficit (43,390) (30,888)
--------- ---------
Total stockholders' equity 89,723 99,439
--------- ---------
Total liabilities and $ 94,324 $ 102,856
stockholders' equity
========= =========
TranS1 Inc.
Statements of Cash Flows
(in thousands)
(Unaudited)
Nine Months Ended
Sept. 30,
----------------------
2008 2007
--------- ---------
Cash flows from operating activities:
Net loss $ (12,502) $ (6,341)
Adjustments to reconcile net loss to net
cash used in operating activities
Depreciation 583 410
Stock-based compensation 2,598 1,774
Allowance for excess and obsolete
inventory 376 168
Provision for bad debts 84 32
Changes in operating assets and
liabilities:
(Increase) decrease in
accounts receivable (611) (2,231)
(Increase) decrease in
inventory (1,804) (1,791)
(Increase) decrease in
prepaid expenses 196 (154)
Increase (decrease) in
accounts payable 772 1,001
Increase (decrease) in
accrued expenses 412 1,062
--------- ---------
Net cash used in operating activities (9,896) (6,070)
--------- ---------
Cash flows from investing activities:
Purchase of property and equipment (1,003) (414)
Purchases of short-term investments (36,495) (2,783)
Sales and maturities of short-term
investments 39,791 10,644
Purchases of long-term investments (14,331) --
--------- ---------
Net cash provided by (used in) investing
activities (12,038) 7,447
--------- ---------
Cash flows from financing activities:
Proceeds from issuance of common stock 188 107
Deferred financing costs -- (1,214)
--------- ---------
Net cash provided by financing activities 188 (1,107)
--------- ---------
Net increase (decrease) in cash and cash (21,746) 270
equivalents
Cash and cash equivalents, beginning
of period 64,676 5,034
--------- ---------
Cash and cash equivalents, end of period $ 42,930 $ 5,304
========= =========